Founded in 2011, David Lamond‘s Lamond Capital Partners filed its first 13F form in 2012, when it held nearly $110 million in assets under management. As of April this year, its assets had swelled to ...

Those following along with Cortexyme, Inc. (NASDAQ:CRTX) will no doubt be intrigued by the recent purchase of shares by David Lamond, Independent Director of the company, who spent a stonking US$1.8m ...

Applied Molecular Transport Inc. (NASDAQ:AMTI) shareholders (or potential shareholders) will be happy to see that the Independent Director, David Lamond, recently bought a whopping US$1.1m worth of ...

Sequoia Capital is Silicon Valley’s most respected venture capital firm, having made money from backing Yahoo, Google, YouTube and many others. It’s been known for some time that Sequoia Capital’s ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today announced that ...

Chinese business ethics based on the 2,500 year old Confucian philosophy could lead the world. International business academic Dean Professor David Lamond says the global financial crisis had shown ...

DermaBlue, a self-described “dermatology practice providing a highly personalized approach to medical and cosmetic skin care,” opens Monday, July 20, at 1998 Hendersonville Road, unit 53.

Technology and healthcare are the only two sectors that Lamond Capital’s equity holdings belonged to in the first quarter, with their respective contributions being 44% and 56%. While the technology ...

Applied Molecular Transport Inc. (NASDAQ:AMTI) shareholders (or potential shareholders) will be happy to see that the Independent Director, David Lamond, recently bought a whopping US$1.1m worth of ...

The third spot is taken by Gilead Sciences, Inc. (NASDAQ:GILD) with Lamond owning 120,000 shares valued at $15.63 million. Lamond Capital decreased its stake in the $153.91 billion healthcare company, ...